Vivaldi Biosciences Acquires Clinical-Stage Influenza Vaccine Assets Vivaldi Biosciences Inc. , a biotechnology company developing live attenuated influenza vaccines against pandemic and seasonal influenza, today announced that it has acquired from Baxter Healthcare SA research and development assets, including intellectual property, clinical data, know-how and materials, for LAIVs in which the gene for influenza nonstructural protein 1 has been fully deleted.
Oct. 10, 2013 - Business Wire via Yahoo! Finance